Speedel appoints new head of communications and investor relations

Basel/Switzerland and Bridgewater NJ/USA, (PresseBox) - Speedel (SWX: SPPN) announces the appointment of the new Head of Corporate Communications and Investor Relations, Dr. Harald F. Schäfer, who joins the company today 21 April 2008. He succeeds Konrad P. Wirz, who held this position ad interim for a few months.

Harald Schäfer, who is a graduated pharmacist Ph.D. and a certified investor relations officer, CIRO, has broad experience in investor relations and in product development in the pharmaceutical industry. After several academic activities in research, and as editor for medical and scientific publishing houses, his professional career has also encompassed responsibility as medical manager in the area of cardiology and finally as investor relations manager of the former Altana AG, Germany.

Dr. Alice Huxley, CEO commented: "We are delighted to have engaged an experienced professional who combines both in-depth knowledge in the pharmaceutical industry in general and the cardiovascular field in particular as well as in investor relations. Harald Schäfer will complement the Speedel management team in this very important function."

Dr. Harald Schäfer added: "Speedel is one of Europe's top tier biopharmaceutical companies, a leader in innovation driven by entrepreneurial spirit. It is an exciting opportunity to join such a dynamic and successful team that is committed to achieving ambitious targets."

Speedel Pharma AG

Speedel is a public biopharmaceutical company that seeks to create value for patients, partners and investors by developing innovative therapies for cardiovascular and metabolic diseases. Speedel is a world leader in renin inhibition, a promising new approach with significant potential for treating cardiovascular diseases. Our lead compound SPP100, Aliskiren (Rasilez/Tekturna[1]) the first-in-class direct renin inhibitor, was in-licensed from Novartis in 1999 and licensed-back to Novartis Pharma in 2002 for further development and commercialisation; SPP100 was approved by the FDA in the US in March 2007, and by the EMEA in the EU in August 2007. Our pipeline covers four different modes of action, and in addition to SPP100, includes SPP301 (an endothelin receptor A antagonist) in Phase II, SPP200 (a direct thrombin inhibitor) in Phase II, the next generation renin inhibitors SPP635 (in Phase Il), SPP1148 and SPP676 (both in Phase I) and several pre-clinical projects, including SPP2745 (aldosterone synthase inhibitor).

Speedel develops novel product candidates through focused innovation and smart drug development from lead identification to the end of Phase II. We either partner with big pharma for Phase III and commercialisation in primary-care indications, or we may ourselves complete Phase III development in specialist indications. Candidate compounds for development and the company's intellectual property come from our late-stage research unit Speedel Experimenta and from in-licensing. Our team of approximately 80 employees, including over 30 experienced pharmaceutical scientists, is located at our headquarters and laboratories in Basel, Switzerland and at offices in New Jersey, USA and Tokyo, Japan.

Speedel was founded in 1998 as a private company. In September 2005 the company's shares were listed on the SWX Swiss Exchange under the symbol SPPN. Further information is available at www.speedel.com.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.